Boosting weight loss after conversional Roux-en-Y Gastric Bypass with liraglutide and placebo use. A double-blind-randomized controlled trial.

Hany M, Torensma B, Ibrahim M, Zidan A, Agayby ASS, Abdelkhalek MH, El Sayed I

International journal of surgery (London, England)1 Mar 2024Cited by 16 (Europe PMC)

PMID38100630PMCIDPMC10942244DOI10.1097/js9.0000000000000990PepBankPUB-38100630

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-SA. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialSafety outcome
After conversional Roux-en-Y gastric bypass, adverse events were recorded in 11 (27.5%) liraglutide patients and none in the placebo group (P < 0.001).
In plain wordsAfter repeat gastric bypass surgery, adverse events occurred in 11 people given liraglutide and in none given placebo.
Peptide
Liraglutide
Outcome
IncreaseAdverse events
Study
n = 80
Comparator
Placebo (normal saline)
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · injection · 6 monthsAs given in this study (human).
Measurements
Adverse events
27.5%
liraglutide
Source sentences
Summary
Adverse events were recorded in 11 (27.5%) patients in the liraglutide, with no adverse events in the placebo group ( P <0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center randomized double-blind placebo-controlled trial included 80 patients randomized into two groups; the liraglutide group (40 patients) who received daily injections of liraglutide, and the placebo group (40 patients) who received normal saline starting at 6 weeks from cRYGB and continued for 6 months.
Report a problemFND-3810063008
02HumanRandomized controlled trialEfficacy outcome
After conversional Roux-en-Y gastric bypass, liraglutide gave a higher mean percentage of total weight loss than placebo at 1 month (10.27 versus 8.41).
In plain wordsAfter repeat gastric bypass surgery, people given liraglutide lost a higher share of their weight at 1 month than people given placebo.
Peptide
Liraglutide
Outcome
IncreasePercentage of total weight loss at 1 month
Study
n: not reported in source
Comparator
Placebo (normal saline)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injection · 6 monthsAs given in this study (human).
Measurements
%TWL
10.27%
liraglutide, 1 month
%TWL
8.41%
placebo, 1 month
Source sentences
Summary
Liraglutide group experienced better WL with a significantly higher mean %TWL at 1 month (10.27±1.39 vs. 8.41±2.08), at 6 weeks (12.65±1.77 vs. 10.47±2.23), at 6 months (18.29 ±1.74 vs. 15.58 ±1.65), and at 12 months 24.15±2.35 versus 22.70±2.13 (all P <0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center randomized double-blind placebo-controlled trial included 80 patients randomized into two groups; the liraglutide group (40 patients) who received daily injections of liraglutide, and the placebo group (40 patients) who received normal saline starting at 6 weeks from cRYGB and continued for 6 months.
Report a problemFND-3810063001
03HumanRandomized controlled trialEfficacy outcome
After conversional Roux-en-Y gastric bypass, liraglutide gave a higher mean percentage of total weight loss than placebo at 6 weeks (12.65 versus 10.47).
In plain wordsAfter repeat gastric bypass surgery, people given liraglutide lost a higher share of their weight at 6 weeks than people given placebo.
Peptide
Liraglutide
Outcome
IncreasePercentage of total weight loss at 6 weeks
Study
n: not reported in source
Comparator
Placebo (normal saline)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injection · 6 monthsAs given in this study (human).
Measurements
%TWL
12.65%
liraglutide, 6 weeks
%TWL
10.47%
placebo, 6 weeks
Source sentences
Summary
Liraglutide group experienced better WL with a significantly higher mean %TWL at 1 month (10.27±1.39 vs. 8.41±2.08), at 6 weeks (12.65±1.77 vs. 10.47±2.23), at 6 months (18.29 ±1.74 vs. 15.58 ±1.65), and at 12 months 24.15±2.35 versus 22.70±2.13 (all P <0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center randomized double-blind placebo-controlled trial included 80 patients randomized into two groups; the liraglutide group (40 patients) who received daily injections of liraglutide, and the placebo group (40 patients) who received normal saline starting at 6 weeks from cRYGB and continued for 6 months.
Report a problemFND-3810063002
04HumanRandomized controlled trialEfficacy outcome
After conversional Roux-en-Y gastric bypass, liraglutide gave a higher mean percentage of total weight loss than placebo at 6 months (18.29 versus 15.58).
In plain wordsAfter repeat gastric bypass surgery, people given liraglutide lost a higher share of their weight at 6 months than people given placebo.
Peptide
Liraglutide
Outcome
IncreasePercentage of total weight loss at 6 months
Study
n: not reported in source
Comparator
Placebo (normal saline)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injection · 6 monthsAs given in this study (human).
Measurements
%TWL
18.29%
liraglutide, 6 months
%TWL
15.58%
placebo, 6 months
Source sentences
Summary
Liraglutide group experienced better WL with a significantly higher mean %TWL at 1 month (10.27±1.39 vs. 8.41±2.08), at 6 weeks (12.65±1.77 vs. 10.47±2.23), at 6 months (18.29 ±1.74 vs. 15.58 ±1.65), and at 12 months 24.15±2.35 versus 22.70±2.13 (all P <0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center randomized double-blind placebo-controlled trial included 80 patients randomized into two groups; the liraglutide group (40 patients) who received daily injections of liraglutide, and the placebo group (40 patients) who received normal saline starting at 6 weeks from cRYGB and continued for 6 months.
Report a problemFND-3810063003
05HumanRandomized controlled trialEfficacy outcome
After conversional Roux-en-Y gastric bypass, the liraglutide group had a higher mean percentage of total weight loss than the placebo group at 12 months (24.15 versus 22.70), after the drug was stopped at 6 months.
In plain wordsAfter repeat gastric bypass surgery, the liraglutide group still had a higher share of weight lost at 12 months than the placebo group.
Peptide
Liraglutide
Outcome
IncreasePercentage of total weight loss at 12 months
Study
n: not reported in source
Comparator
Placebo (normal saline)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injection · 6 monthsAs given in this study (human).
Measurements
%TWL
24.15%
liraglutide, 12 months
%TWL
22.7%
placebo, 12 months
Source sentences
Summary
Liraglutide group experienced better WL with a significantly higher mean %TWL at 1 month (10.27±1.39 vs. 8.41±2.08), at 6 weeks (12.65±1.77 vs. 10.47±2.23), at 6 months (18.29 ±1.74 vs. 15.58 ±1.65), and at 12 months 24.15±2.35 versus 22.70±2.13 (all P <0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center randomized double-blind placebo-controlled trial included 80 patients randomized into two groups; the liraglutide group (40 patients) who received daily injections of liraglutide, and the placebo group (40 patients) who received normal saline starting at 6 weeks from cRYGB and continued for 6 months.
Report a problemFND-3810063004
06HumanRandomized controlled trialEfficacy outcome
After conversional Roux-en-Y gastric bypass, percentage of excess weight loss was significantly higher with liraglutide than placebo at all time points.
In plain wordsAfter repeat gastric bypass surgery, people given liraglutide lost a higher share of their excess weight than people given placebo at every time point.
Peptide
Liraglutide
Outcome
IncreasePercentage of excess weight loss
Study
n: not reported in source
Comparator
Placebo (normal saline)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injection · 6 monthsAs given in this study (human).
Source sentences
Summary
For %EWL, this was also significantly higher in the liraglutide group at all time points.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center randomized double-blind placebo-controlled trial included 80 patients randomized into two groups; the liraglutide group (40 patients) who received daily injections of liraglutide, and the placebo group (40 patients) who received normal saline starting at 6 weeks from cRYGB and continued for 6 months.
Report a problemFND-3810063005
07HumanRandomized controlled trialEfficacy outcome
After conversional Roux-en-Y gastric bypass, six patients (15.8%) on liraglutide and none on placebo had total weight loss above 20% at 6 months (P = 0.029).
In plain wordsAfter repeat gastric bypass surgery, more people given liraglutide than placebo lost over 20% of their weight at 6 months.
Peptide
Liraglutide
Outcome
IncreaseProportion with total weight loss above 20% at 6 months
Study
n: not reported in source
Comparator
Placebo (normal saline)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · injection · 6 monthsAs given in this study (human).
Measurements
Responders
15.8%
liraglutide, %TWL >20% at 6 months
Source sentences
Summary
A %TWL of greater than 20% at 6 months of treatment was recorded in six (15.8%) patients in the liraglutide group and none in the placebo group ( P =0.029).
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center randomized double-blind placebo-controlled trial included 80 patients randomized into two groups; the liraglutide group (40 patients) who received daily injections of liraglutide, and the placebo group (40 patients) who received normal saline starting at 6 weeks from cRYGB and continued for 6 months.
Report a problemFND-3810063006
08HumanRandomized controlled trialEfficacy outcome
After conversional Roux-en-Y gastric bypass, changes in metabolic biomarkers were comparable between the liraglutide and placebo groups.
In plain wordsAfter repeat gastric bypass surgery, changes in metabolic blood markers were similar with liraglutide and placebo.
Peptide
Liraglutide
Outcome
No significant changeMetabolic biomarkers
Study
n: not reported in source
Comparator
Placebo (normal saline)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · injection · 6 monthsAs given in this study (human).
Source sentences
Summary
Both groups had comparable changes in metabolic biomarkers.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center randomized double-blind placebo-controlled trial included 80 patients randomized into two groups; the liraglutide group (40 patients) who received daily injections of liraglutide, and the placebo group (40 patients) who received normal saline starting at 6 weeks from cRYGB and continued for 6 months.
Report a problemFND-3810063007
09HumanRandomized controlled trialSafety outcome
After conversional Roux-en-Y gastric bypass, both groups had only Clavien-Dindo grade I and II complications (5.0 and 2.5%); 90.0 and 97.5% were low-risk by global outcome benchmark.
In plain wordsAfter repeat gastric bypass surgery, complications in both groups were minor, and most patients were low-risk.
Peptide
Liraglutide
Outcome
Not applicablePostoperative complications (Clavien-Dindo)
Study
n: not reported in source
Comparator
Placebo (normal saline)
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · injection · 6 monthsAs given in this study (human).
Source sentences
Summary
Both groups had Clavien-Dindo scores I and II (5.0 and 2.5%), and GOB values indicated that 90.0 and 97.5% were low-risk patients.
1 context sentence(design, population, supporting numbers)
Summary · context
This single-center randomized double-blind placebo-controlled trial included 80 patients randomized into two groups; the liraglutide group (40 patients) who received daily injections of liraglutide, and the placebo group (40 patients) who received normal saline starting at 6 weeks from cRYGB and continued for 6 months.
Report a problemFND-3810063009

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.